Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation

This study has been terminated.
(This study was terminated because of recruitment difficulties.)
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier:
NCT00983736
First received: September 22, 2009
Last updated: August 24, 2012
Last verified: November 2010
  Purpose

The purpose of this clinical trial is to test an experimental drug therapy called Tramadol Hydrochloride (HCl) Orally Disintegrating Tablets (ODT) ("Tramadol HCl ODT" or the "study drug"). The patient and the patient's partner are being asked to be in this clinical trial because they have a condition called Premature Ejaculation.


Condition Intervention Phase
Premature Ejaculation
Drug: Tramadol Hydrochloride
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation

Resource links provided by NLM:


Further study details as provided by Valeant Pharmaceuticals International, Inc.:

Primary Outcome Measures:
  • Increase in IELT (Intravaginal ejaculatory time) [ Time Frame: Per attempt at sexual intercourse ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy of using Tramadol for Premature Ejaculation [ Time Frame: At each attempt ] [ Designated as safety issue: No ]

Estimated Enrollment: 1050
Study Start Date: October 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active Drug: Tramadol Hydrochloride

89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).

Subject will take the study drug for about 27 weeks.

Placebo Comparator: Placebo Drug: Placebo

89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).

Subject will take the study drug for about 27 weeks.


  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects are eligible for study participation if all of the following criteria are met:

  1. Male subject and female partner to provide written informed consent prior to the performance of any study-specific procedures;
  2. Candidates will be male subjects aged 18-65 years inclusive, with lifelong premature ejaculation ("lifelong" is defined as starting at the time the subject became sexually active) with an IELT of ≤120 seconds as documented at Visit 2.
  3. History of premature or rapid ejaculation, determined by following criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV TR):

    1. Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after vaginal insertion and before the person wishes it, taking into account factors that affect duration of the excitement phase such as age, novelty of the sexual partner or situation and recent frequency of sexual activity
    2. The disturbance causes marked distress or interpersonal difficulty
    3. The premature ejaculation is not due exclusively to the direct effects of a substance (ab)use
  4. In a stable, monogamous, heterosexual relationship (> 6 months).
  5. Willing and able to take study medication as directed at least 2 hours prior to sexual intercourse according to protocol;
  6. Subject willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews:
  7. Female sexual partner willing and able to complete the therapeutic trial, all sexual behavior logs, IELT assessments, questionnaires and interviews;
  8. Able to understand the study procedures, complete the assessments, and communicate with study personnel;
  9. Subject and partner willing and able to engage in vaginal intercourse at least three times between visits to yield at least three events of vaginal intercourse ;
  10. Subject and partner willing to use a reliable contraceptive method during the trial period if the partner is not menopausal;
  11. Partner willing to take pregnancy tests at Visits 1 and 2
  12. Subject willing to list and document prescription and non-prescription drug use during the study;
  13. Have a negative urine drug screen at Visits 1 and 2;
  14. Be in good general health as determined by medical history and physical examination and expected by the Investigator to complete the study as designed.

Exclusion Criteria:

Subjects are not eligible for study participation if any of the following criteria are met:

  1. Premature ejaculation attributable to situational or relationship issues;
  2. Evidence or a history of other significant psychiatric disorder as defined as requiring therapy or medication;
  3. Subjects who in the Investigator's opinion are at significant risk of suicide.
  4. Physical illnesses

    i.History of seizures

    ii.Prostatitis (current)

    iii.Urethritis or other urinary tract infections (current)

    iv.Prior genital surgery (other than vasectomy or circumcision)

    v.Uncontrolled Diabetes mellitus

    vi.Respiratory Depression

    vii.Thyroid disease

    viii.Chronic moderate to severe neurological disease

    ix.Significant heart disease treated with cardiac drugs

    x.Chronic liver disease

    xi.Chronic kidney disease

    xii.History of cardiovascular disease (myocardial infarction, congestive heart failure, angina, coronary artery disease or stroke)

    xiii.Known to be a carrier of the hepatitis B surface antigen, hepatitis C virus antibody, and/or immunodeficiency virus-1 and/ or 2 antibodies

    xiv.Other disorder that may cause sexual dysfunction

  5. Other sexual dysfunction:

    i.Erectile dysfunction. As defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR), the diagnostic criteria for male erectile disorder (302,72) erectile dysfunction includes:

    A.Persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate erection.

    B.The disturbance causes marked distress or interpersonal difficulty. ii.Primary reduced sexual desire unrelated to premature ejaculation

  6. Sexual intercourse usually less than once per week;
  7. Partner sexual dysfunction (for example dyspareunia or other conditions considered relevant);
  8. Current use of dapoxetine;
  9. Current use of any tramadol;
  10. Sensitivity to phenylketone;
  11. Any history of abuse of prescription opioids and/or illicit/illegal addictive drugs;
  12. Has a known hypersensitivity to heparin or history of heparin induced thrombocytopenia;
  13. Use of medication, within the preceding 30 days, with potential to cause sexual dysfunction: (See Appendix 2 for a list of excluded medications)

    i.Antidepressants - all types

    ii.Antipsychotic medication

    iii.Antihypertensive medication, unless on a stable dose > 6 months

    iv.Hormonal drugs

    v.Chemotherapy

    vi.Others: cimetidine, clofibrate,quinidine

  14. Recent psychotropic drug use (within the past 30 days);
  15. A history of alcohol abuse or dependence within the past 6 months as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV TR);
  16. Initiation of psychosexual counseling during the screening, baseline or treatment periods;
  17. Partner positive pregnancy test at Visit 1 or 2;
  18. History of clinically significant intolerance or a known hypersensitivity to tramadol, such that treatment with it is contraindicated;
  19. The Investigator anticipates that the subject will be unable to comply with the protocol;
  20. Received any investigational drug within 30 days prior to Visit 1 or is scheduled to receive an investigational drug during the course of this study;
  21. Has preplanned surgery or procedures that would interfere with the course of the study.
  22. A family member (other than the female partner), a staff member, or relative of a staff member..
  23. Significant laboratory abnormality as determined by the Investigator at Visit 1;
  24. Significant ECG abnormality at Visit 1 as determined by the Investigator;
  25. Any other illnesses, conditions or practices that in the Investigator's opinion could interfere with the collection and/or interpretation of study results (couples using the "Withdrawal Method" of birth control will be excluded from the study).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00983736

  Show 48 Study Locations
Sponsors and Collaborators
Valeant Pharmaceuticals International, Inc.
Investigators
Principal Investigator: Peter Nyiradi, MD Mediroyal Prevention Center
  More Information

No publications provided by Valeant Pharmaceuticals International, Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Valeant Pharmaceuticals International, Inc.
ClinicalTrials.gov Identifier: NCT00983736     History of Changes
Other Study ID Numbers: BVF-324-302
Study First Received: September 22, 2009
Last Updated: August 24, 2012
Health Authority: Bulgaria: Ministry of Health
Czech Republic: Ethics Committee
Hungary: National Institute of Pharmacy
Poland: Ethics Committee
Romania: Ethics Committee

Additional relevant MeSH terms:
Tramadol
Sexual Dysfunctions, Psychological
Sexual and Gender Disorders
Mental Disorders
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid

ClinicalTrials.gov processed this record on April 17, 2014